Meridian Bioscience Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Meridian Bioscience heeft een totaal eigen vermogen van $368.1M en een totale schuld van $25.0M, wat de schuld-eigenvermogensverhouding op 6.8% brengt. De totale activa en totale passiva bedragen respectievelijk $463.1M en $95.0M. De EBIT Meridian Bioscience is $75.6M waardoor de rentedekking 64.5 is. Het heeft contanten en kortetermijnbeleggingen van $81.5M.
Belangrijke informatie
6.8%
Verhouding schuld/eigen vermogen
US$25.00m
Schuld
Rente dekkingsratio | 64.5x |
Contant | US$81.45m |
Aandelen | US$368.06m |
Totaal verplichtingen | US$95.04m |
Totaal activa | US$463.10m |
Recente financiële gezondheidsupdates
Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet
Jun 27These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely
Jul 19Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly
Mar 31Recent updates
Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M
Aug 05Meridian Bioscience: High-Probability Merger Arbitrage
Jul 26Meridian Bioscience downgraded at William Blair on $1.53B acquisition
Jul 07Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet
Jun 27Meridian Bioscience: Correctly Valued
Jun 26Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital
Jun 09Meridian Bioscience: Deceptively Priced
Mar 14Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns
Feb 03These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely
Jul 19If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy
Jul 08Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine
May 10Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation
May 08Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly
Mar 31Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?
Mar 11Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%
Feb 24Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues
Feb 09Meridian expands production capacity for COVID-19 tests with NIH funding
Feb 03Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?
Jan 27Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $210.6M ) VIVO } overtreffen de korte termijn passiva ( $58.0M ).
Langlopende schulden: De kortetermijnactiva VIVO ( $210.6M ) overtreffen de langetermijnschulden ( $37.1M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: VIVO heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van VIVO is de afgelopen 5 jaar gedaald van 32.2% naar 6.8%.
Schuldendekking: De schuld van VIVO wordt goed gedekt door de operationele kasstroom ( 329.4% ).
Rentedekking: De rentebetalingen op de schuld van VIVO worden goed gedekt door EBIT ( 64.5 x dekking).